Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Subscribe To Our Newsletter & Stay Updated